Cadrenal Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
CVKD$1.44+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets at December 31, 2024 and 2023
BALANCE SHEETS
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets: | ||
| Current assets: | ||
| Cash and cash equivalents | $10,017,942 | $8,402,500 |
| Interest receivable | 38,153 | 37,248 |
| Prepaid expenses and other current assets | 42,257 | 52,425 |
| Deferred offering costs | 14,445 | - |
| Total current assets | 10,112,797 | 8,492,173 |
| Property, plant and equipment, net | 6,944 | 2,287 |
| Right of use assets | - | 20,998 |
| Other assets | 3,792 | 3,792 |
| Total assets | $10,123,533 | $8,519,250 |
| Liabilities and Stockholders' Equity: | ||
| Current liabilities: | ||
| Accounts payable | $1,502,468 | $167,319 |
| Accrued liabilities | 1,181,490 | 638,206 |
| Operating lease liability | - | 21,350 |
| Total current liabilities | 2,683,958 | 826,875 |
| Total liabilities | 2,683,958 | 826,875 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023 | - | - |
| Common stock, $0.001 par value; 75,000,000 shares authorized, 1,782,486 shares issued and outstanding as of December 31, 2024; 868,184 shares issued and outstanding as of December 31, 2023 (1) | 1,782 | 868 |
| Additional paid-in capital (1) | 33,160,576 | 22,762,922 |
| Accumulated deficit | (25,722,783) | (15,071,415) |
| Total stockholders’ equity | 7,439,575 | 7,692,375 |
| Total liabilities and stockholders’ equity | $10,123,533 | $8,519,250 |
| (1) | All share and per share information has been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on August 20, 2024. See Note 6, Stockholders’ Equity for additional information. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.